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Background. This study was performed to investigate the inﬂuence of a short-term treatment with pioglitazone versus placebo
on inﬂammatory activation of mononuclear cells (mRNA expression/protein secretion of inﬂammatory markers). Methods
and Results. Sixty-three patients with well-controlled type 2 diabetes (52 males, 11 females, age (Mean±SD): 66 ± 7yrs,
disease duration: 6.6 ± 9.6yrs, HbA1c: 6.7 ± 0.6%) were randomized to additional 45mg of pioglitazone or placebo to
their existing metformin and sulfonylurea therpay for four weeks in a double-blind study design. Protein risk marker levels
(hsCRP, MMP-9, MCP-1, etc.) and the expression of NFκB subunits and NFκB-modulated cytokines from isolated peripheral
monocyte/macrophages were determined at baseline and endpoint. There were no changes in HbA1c, but signiﬁcant biomarker
improvements were seen with pioglitazone only. The mRNA marker expression was downregulated by pioglitazone and further
up-regulated with placebo (e.g., P105 pioglitazone: −19%/placebo: +6%, RelA: −20%/+2%, MMP−9: −36%/+9%, TNFα:
−10%/+14%, P<0.05 between groups in all cases). Conclusions. Pioglitazone very rapidly down-regulated the activated state
of peripheral monocytes/macrophages as assessed by mRNA expression of NFκBa n dN F κB-modulated cytokines and decreased
plasma levels of cardiovascular risk marker proteins independent of glycemic control.
1.Introduction
Obesity has been demonstrated to be associated with
metabolic syndrome and cardiovascular disease, includ-
ing severe complications, like acute coronary syndrome,
myocardial infarction, and stroke [1, 2]. An increase in
body weight is usually accompanied by an increase in
oxidative stress [3] and an elevation in the tissue expression
and plasma levels of proinﬂammatory cytokines, such as
tumor necrosis factor-α (TNFα)[ 4], interleukin-6 (IL-
6) [5, 6], plasminogen activator-inhibitor-1 (PAI-1) [7],
and others [8]. This protein expression proﬁle indicates
the prevalence of a chronic systemic inﬂammation, and
diﬀerentiating preadipocytes deriving from mesenchymal
stem cells especially in the visceral lipid tissue are considered
to be a major source for these cytokines and proteins [9].
It is believed that the crosstalk between the preadipocytes
and other tissues contributes to a general up-regulation of
the immune system, including an activation of circulating
monocytes and macrophages, resulting in an increased risk
for atherosclerosis and vascular disease [10, 11].
It has been demonstrated by Ghanim and Coworkers
that circulating mononuclear cells in obese patients are in2 PPAR Research
a proinﬂammatory state with an increase in intranuclear
NF-κB binding, a decrease in IκB-ß, and an increase in the
transcription of proinﬂammatory genes regulated by NF-κB,
including migration inhibitory factor (MIF), IL-6, TNFα,
and matrix metalloproteinase 9 (MMP-9) [12]. The same
group was able to demonstrate that an increased plasma
concentration of MIF and an increased transcription of MIF
mRNA in mononuclear cells, which was related to the body-
mass index and hsCRP concentrations, could be reduced by
a six-week treatment with metformin in eight nondiabetic
patients with obesity. The authors concluded that metformin
might have beneﬁcial eﬀects on cardiovascular mortality in
patients with type 2 diabetes [13], which is in part conﬁrmed
by the few currently existing larger outcome trials on this
topic [14, 15]. The same group also showed that the insulin-
sensitizing drug troglitazone was able to suppress NF-κB
activity and stimulate IκB in nondiabetic obese patients,
which gave evidence for an anti-inﬂammatory eﬀect of this
drug [16]. Troglitazone was, however, taken from the market
because of hepatotoxicity [17].
It has been shown in randomized prospective trials
that treatment with pioglitazone, another agonists to the
peroxisome proliferators-activated receptor γ,m a yi m p r o v e
clinical and laboratory surrogate markers for atherosclerosis
and cardiovascular risk, like intima-media thickness, hsCRP,
or MMP-9 independent of glycemic control [18–20], and
that it may even improve macrovascular outcome in type 2
diabetic patients when used in secondary prevention [21–
23]. The anti-inﬂammatory and antithrombotic eﬀects of
thiazolidinedionesoccurveryrapidlyandsigniﬁcantlyearlier
as compared to the metabolic and glycemic eﬀects of these
drugs [24, 25].
In this study, we explored the short-term eﬀects of an
addition of pioglitazone (versus placebo) to an existing
eﬀective oral antidiabetic therapy with metformin and/or
sulfonylurea on the proinﬂammatory activation of circulat-
ing mononuclear cells in well-controlled patients with type
2 diabetes mellitus and elevated risk for atherosclerosis. For
this purpose, we investigated the mRNA expression of the
inhibitors to NF-κB( I κB-α and IκB-β)[ 26], p105 (precursor
to the p50 subunit), and Rel-A (p65 subunit) as measures
for the quantity of intranuclear NF-κB[ 27], and several
proinﬂammatory mediators and markers that are known
to be modulated by NF-κB, such as TNFα,I L - 6 ,M I F ,a n d
MMP-9 [5, 12, 28] before and after four weeks of treatment..
2. Patientsand Methods
Thisinvestigationwasperformedasadouble-blind,placebo-
controlled, randomised multicentre study in patients with
type 2 diabetes and established atherosclerosis. Inclusion cri-
teria were an age between 20 and 80years, an HbA1c < 8.5%,
an angiographically conﬁrmed coronary artery disease, and
an activated chronic systemic inﬂammation (characterized
by an increased hsCRP level ≥ 1mg/L). Patients had to be
on any stable oral antidiabetic treatment with the exception
of a thiazolidinedione for at least 3 months. Main exclusion
criteria were systemic inﬂammation of other origin, invasive
cardiovascular intervention within the last 3 months, history
of heart failure (NYHA I-IV), major hepatic or renal disease,
and progressive fatal disease. The study was approved by the
localethicalreviewboardandthenationalregulatoryagency,
and all patients provided a written informed consent prior
to study inclusion (registration number NCT00479986 at
http://www.clinicaltrials.gov/).
The patients were randomised by a telephone random-
ization procedure to either receive 45mg pioglitazone or
placebo in addition to their individual oral antidiabetic
treatment for 4 weeks. Primary objective was the change
from baseline of MMP9 levels as an indicator of macrophage
activation. Secondary objectives were the changes of other
indicators of chronic systemic inﬂammation (e.g., plasma
hsCRP and MCP-1 levels, etc.) or insulin resistance as
indicated in Table 2. Blood for the measurement of fast-
ing glucose, MMP-9, and hsCRP was taken at baseline
and after 3, 7, 10, 14, and 28 days of study treatment.
Blood for assessment of the mRNA expression proﬁle of
circulating mononuclear cells as well as for assessment of
circulatingplasmalevelsofHbA1c,insulin,intactproinsulin,
adiponectin, IL-6, sCD40L, P-selectin, MIF, Angiotensin II,
complement factor 3, and blood lipids were obtained at
baseline and at the end of the study. Insulin resistance was
calculated using the HOMAIR score at baseline and study
endpoint as published previously [29, 30].
2.1. Laboratory Methods. HbA1c was measured by means
of an HPLC method (Menarini, Neuss), and lipids were
assessed by standard dry chemistry (Olympus, Hamburg,
Germany). Immunoassays were applied to determine the
plasma concentrations of insulin (CLIA, Invitreon, Cardiﬀ,
UK), intact proinsulin (CLIA, Invitreon, Cardiﬀ,U K ) ,
adiponectin (RIA, Linco, St. Charles, MO), IL-6 (Elisa,
IBL, Hamburg, Germany), MMP-9 (ELISA, R&D Sys-
tems, Wiesbaden, Germany), MCP-1 (ELISA, R&D Systems,
Wiesbaden, Germany), sCD40L (ELISA, R&D Systems,
Wiesbaden, Germany), P-selectin (R&D Systems, Wies-
baden, Germany), TNFα ( E L I S A ,I B L ,H a m b u r g ,G e r m a n y ) ,
MIF (R&D Systems, Wiesbaden, Germany), Angiotensin II
(ELISA, DRG-Diagnostics, Marburg, Germany), and com-
plement factor C3 (ELISA, BioCat, Heidelberg, Germany).
2.2. Isolation of Mononuclear Cells and mRNA Extraction.
Isolation of MNC from whole blood was performed as a
density gradient centrifugation by means of the ACCUS-
PIN System-HISTOPAQUE-1077 (Sigma-Aldrich Chemie
GmbH, Steinheim, Germany). The isolation of macrophages
and monocytes from the collected cells was performed
by MACS magnetic cell sorting with CD14 MicroBeads
(human) (Miltenyi Biotec GmbH, Bergisch Gladbach, Ger-
many). The CD14-positive (CD14+) cells (macrophages and
monocytes) were ﬁrst magnetically labelled with MACS
CD14 MicroBeads. The cell suspension was loaded on an
MS MACS Column which was placed in the magnetic ﬁeld
of a MiniMACS Separator. The magnetically labelled CD14+
cells were retained in the column and separated from the
unlabelled cell fraction.PPAR Research 3
2.3. mRNA Isolation from Macrophages and Monocytes and
Reverse Transcription. The mRNA isolation from macro-
phages and monocytes was performed with the High
Pure RNA Isolation Kit (Roche Applied Science, Penzberg,
Germany). The cells were ﬁrst lysed and the intact and
undegraded RNA was adsorbed to a glass ﬁbre ﬂeece. Simul-
taneously, RNAses were inactivated. Furthermore, residues
of contaminating DNA were digested, and the RNA was
puriﬁed from salts, proteins, and other impurities. Purity of
the isolated mRNA was assessed by real-time PCR (Light-
Cycler II, Roche Diagnostics, Mannheim, Germany). The
transcription of mRNA in cDNA was performed on a ther-
mocycler (Biozym Diagnostik GmbH, Oldendorf, Germany)
according to a standardized protocol (“Transcriptor First
Strand cDNA Synthesis Kit”, Instruction Manual Version 1,
2004, Roche Applied Science, Penzberg, Germany).
2.4. Primers for PCR Reactions. Sequence-speciﬁc primers
were designed by TIB MOLBIOL (Syntheselabor GmbH,
Berlin, Germany) to amplify the gene sequences of Rel-
A, p105, IκB-α,I κB-ß, and IL-6. The primers for TNF-
α were taken from “Rapid Cycle Real-Time PCR Methods
and Applications Quantiﬁcation” [31]. The primers for
MIF and MMP9 were reproduced from previous reports
[12, 32]. A list of the primers used for the quantiﬁcation
experiments, the primer-speciﬁc PCR protocols, and the
speciﬁcampliﬁcationproductmelting points areprovided in
Table 1. An additional agarose gel electrophoresis assay was
performed to verify the correct length of the ampliﬁcation
products.
2.5. Quantiﬁcation of mRNA Expression Proﬁles. The RNA
quantiﬁcation in this study was performed by means of a
calibrator-normalized relative quantiﬁcation method based
ontheLightCyclerIIsystem(RocheDiagnostics,Mannheim,
Germany), where quantiﬁcation of a target and a reference
gene is a function of PCR eﬃciency and the sample crossing
point. The sample crossing point is the ampliﬁcation cycle
during an ampliﬁcation assay, at which the ﬂuorescence of
a probe rises above background ﬂuorescence. This occurs
usually at the second derivative maximum (fastest change
in ﬂuorescence). The calibrator, a positive sample for the
investigated gene product, must have a constant ratio of
target gene expression to reference gene expression. In
these experiments, ß-actin is the most abundant protein in
eukaryotic cells with constant expression [33]. The results
of the calibrator-normalized quantiﬁcation are expressed as
the target/reference ratio of each sample divided by the
target/reference ratio of the calibrator. The principle of this
method is the determination of the relative amount of the
target gene and the reference gene for each sample and for
the calibrator. Quantiﬁcation results are provided as normal-
ized ratio ((target marker concentration [sample]/reference
concentration [sample])/(target marker concentration [cali-
brator]/reference concentration [calibrator]). For each RNA
marker investigated in this study, a standard curve was
created, to be able to compare the unknown values of the
patient samples to a standard value of a calibrator and to
calculate the ratios relevant for quantiﬁcation of the levels of
mRNA expression. All experiments were performed in triple
replications.
2.6. Statistical Analysis. Data are presented as arithmetic
mean ± standard deviation (SD) for continuous variables or
mean ± SEM for percent changes from baseline and as the
number/proportion of patients for categorical variables. For
the changes from baseline of the eﬃcacy parameters, one-
sided P values for within-group treatment diﬀerences were
calculated, using the paired t-test procedure. In addition,
ANOVAwasperformedwiththebaselinevaluesoftheobser-
vation parameters as covariates. Wilcoxon’s two-sample test
was used to calculate one-sided P values for between-group
treatment diﬀerences. No transformations were applied to
the secondary eﬃcacy parameters. All inferential statistical
analyses were performed in an exploratory sense, and all P
values < 0.05 were interpreted as statistically signiﬁcant. The
authors had full access to the data and take responsibility for
its integrity. All authors have read and agree to the paper as
written.
3. Results
In total, 63 patients matching the inclusion and exclusion
criteria could be included into this investigation (11 women,
52 men; age: 65.6 ± 6.9 years (range: 45–77 years); dis-
ease duration: 6.6 ± 9.6 years (range: 0–58 years), HbA1c:
6.7±0.6%; BMI: 30.7 ± 4.2kg/m 2). All but one patient
had a known prevalence of cardiovascular disease (98.4%),
and 59 suﬀered from hypertension (93.6%). A total of 9
patientswerecurrentsmokers(14.3%)andother37reported
smoking in the past (58.7%). The study drugs were well
tolerated, and all but one patient in the pioglitazone arm
completed the study per protocol. This patient dropped out
based on a personal decision after realizing a mismatch
between personal schedules and study visit requirements.
The change in fasting glucose concentrations and in the
inﬂammatory cardiovascular risk markers MMP-9, MCP-1,
and hsCRP during the observation period is provided in
Figure 1. While a slight but nonsigniﬁcant decrease in fasting
glucose could be observed with pioglitazone, the same group
showed a fast and signiﬁcant decrease in MMP-9 and hsCRP
that was not seen in the placebo group. There was no
signiﬁcant change from baseline to endpoint in HbA1c
in this well-controlled patient population in any of the
two treatment groups, but a signiﬁcant improvement in
insulin resistance and the metabolic syndrome as indicated
by a decrease in the HOMAIR score, a decrease in intact
proinsulin concentrations, and an increase in adiponectin
values was observed in patients treated with pioglitazone
(P<0.001 versus placebo at endpoint in all cases).
The mean absolute values for all determined plasma
proteins and the other observation parameters at baseline
and endpoint are provided in Table 2. There were signiﬁcant
improvements in many of these markers after 4 weeks
of pioglitazone treatment, indicating an overall reduction
of the inﬂammatory situation in the circulating blood,4 PPAR Research
Table 1: Primer composition and PCR protocols.
Gene Forward primer
Reverse primer
Annealing
temperature [◦C] Annealing time [s] Elongation time [s] Product melting
temperature [◦C]
Rel-A CAGTACCTGCCAGATACAGACGA
GGGAAGGCACAGCAATG 63 10 7 88
P105 TGATGATTTACTAGCACAAGGAGACAT
TGTACCCCCAGAGACCTCATAG 65 10 9 85
IκB-α CTGATGTCAATGCTCAGGAGCC
TGTGTCATAGCTCTCCTCATCCTCAC 68 10 11 89
IκB-ß CTGAAAACTACGAGGGCCA
CCTCCACTGCCAAATGAAG 64 5 8 91
TNF-α CCCAGGGACCTCTCTCTAATC
ATGGGCTACAGGCTTGTCACT 64 10 8 87
IL-6 CCCATGCAGGCACTTACTAC
ACGTCTTCTTGAACCTCAGAACA 63 5 4 86
MIF CGGACAGGGTCTACATCAA
CTTAGGCGAAGGTGGAGTT 63 5 4 84
MMP-9 CCCATTTCGACGATGACGAGTTGTG
GGAGTAGGATTGGCCTTGGAAGATG 64 10 13 92
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Figure 1: Changes in plasma concentrations of MMP-9, MCP-1, hsCRP, and glucose during the four-week observation period.PPAR Research 5
Table 2: Clinical and biochemical observation parameters at baseline and after 4 weeks in both treatment arms.
Pioglitazone Placebo
Baseline Endpoint Baseline Endpoint
HbA1c [%] 7.0 ±1.16 .8 ±0.96 .7 ±0.66 .6 ±0.7
BMI [kg/m2]3 1 .0 ±4.33 1 .4 ±4.5
∗ 30.5 ± 4.13 0 .4 ±4.2
Systolic blood pressure [mmHg] 144 ±15 137 ±18
∗ 141 ± 19 139 ±20
Diastolic blood pressure [mmHg] 83 ±11 80 ±11 78 ±11 79 ±9
Waist/hip ratio 1.00 ±0.05 1.00 ±0.07 1.00 ±0.06 1.00 ±0.06
Glucose [mg/dL] 142 ±40 122 ± 35
∗∗∗ 128 ± 23 131 ±29
Insulin [μU/mL] 17 ±10 12 ± 7∗∗∗ 18 ±10 18 ± 11+
HOMAIR 5.9 ±4.43 .9 ±2.6
∗∗∗ 6.0 ±3.56 .4 ± 4.5+
Adiponectin [mg/dL] 8.7 ±3.52 2 .1 ± 9.1
∗∗∗ 8.3 ±4.78 .2 ± 4.2+++
Intact proinsulin [pmol/L] 30 ±37 19 ±17
∗ 24 ±19 24 ±20
hsCRP [mg/L] 2.9 ±1.71 .9 ± 1.7
∗∗ 3.2 ±2.63 .2 ±2.6+
MMP-9 [μg/L] 344 ±118 284 ± 101
∗∗ 388 ±147 391 ± 121+++
MCP-1 [μg/L] 454 ±130 406 ±106
∗ 446 ±129 468 ±127+
Total cholesterol [mmol/L] 4.63 ±0.99 4.78 ±1.09 4.60 ±1.10 4.61 ±1.00
LDL cholesterol [mmol/L] 2.46 ±0.80 2.52 ±0.76 2.21 ±0.93 2.21 ±0.90
HDL cholesterol [mmol/L] 1.18 ±0.24 1.26 ± 0.26
∗∗ 1.12 ±0.21 1.13 ±0.19+
Triglycerides [mmol/L] 1.84 ±1.14 1.72 ±0.99 2.41 ±2.22 2.53 ±1.73+
sICAM [μg/L] 326 ±90 319 ±86 304 ± 56 310 ±60
sVCAM [μg/L] 915 ±409 943 ±452 797 ±193 807 ±220
sCD40L [μg/L] 1.6 ±1.81 .1 ±1.11 .4 ±1.21 .0 ±0.9
P-selectin [μg/L] 95 ±20 93 ±22 96 ±26 98 ±26
IL-6 [ng/L] 3.3 ±0.53 .2 ±0.13 .3 ±0.33 .3 ±0.4
Angiotensin II [μg/L] 10.2 ±9.28 .0 ±8.8
∗ 9.2 ±8.21 0 .1 ±10.1
Complement factor C3 [g/L] 1.6 ±0.41 .5 ±0.31 .6 ±0.41 .7 ±0.5
MIF [μg/L] 10.4 ±5.39 .6 ±3.51 0 .1 ± 4.11 0 .3 ±4.3
Within-group comparison: ∗: P<0.05; ∗∗: P<0.01; ∗∗∗: P<0.001 versus baseline.
Between groups for changes from baseline: +: P<0.05; ++: P<0.01; +++: P<0.001.
an improvement in endothelial and thrombocyte function,
and an improvement in the metabolic risk situation. The
diﬀerences from baseline to endpoint in the pioglitazone
groupandbetweenthetreatmentgroupsatendpointreached
thelevelofstatisticalsigniﬁcanceformanyoftheobservation
parameters.
The quantiﬁcation of the mRNA expression of the inves-
tigated proinﬂammatory cytokines in relation to a calibrator
gene (ß-actin) is provided in Table 3. The relative expres-
sion of all proinﬂammatory markers increased in patients
treated with placebo and decreased in patients on additional
pioglitazone therapy, while the expression of the inhibitory
markers changed inversely. The diﬀerence between the
groups at endpoint was statistically signiﬁcant for MMP9,
TNFα, RelA, and p105. The percent changes in the mRNA
expression of the observed biomarkers for both treatments
are provided in Figure 2. The changes in MMP-9 mRNA
expression were reﬂected by the corresponding protein
concentrations.Theoverallexpressionpatterndemonstrated
a comprehensive decrease in the inﬂammatory state of the
circulating monocytes during pioglitazone therapy, while a
further increase of proinﬂammatory mRNA expression was
observed with placebo.
There were no clinically relevant adverse events observed
in the study. In particular, there were no cases of severe
hypoglycaemia reported.
4. Discussion
The participants of our study had a good glycemic control
by means of metformin and/or sulfonylurea drugs. The
addition of pioglitazone induced a rapid reduction in
the inﬂammatory expression state of circulating mono-
cyte/macrophages,whichwentinparallelwithareductionof
the plasma concentrations of corresponding plasma proteins
and additional biomarkers for chronic inﬂammation in
diabetic patients, which could not be observed in the
placebo arm. Although the diﬀerences in mRNA marker
expression between the two observation groups did not
reach the level of statistical signiﬁcance for all markers,
the general expression pattern uniformly points into the
directionofacomprehensivedownregulationofmacrophage
activation by pioglitazone. The expression of the NF-κB-
related proteins (RelA and p105) and of NF-κB-regulated
proteins (TNF-α, MIF, and MMP-9) was signiﬁcantly or
slightly but nonsigniﬁcantly reduced, while the expression6 PPAR Research
Table 3: mRNA expression of NFκBa n dN F κB-modulated cytokines in circulating peripheral mononuclear cells at baseline and after 4
weeks of therapy with pioglitazone or placebo (reference gene: ß-actin).
Pioglitazone Placebo
Baseline Endpoint Baseline Endpoint
p105 (p50 subunit of NF-κB) 1.63 ±0.80 1.33 ±0.46
∗ 1.35 ±0.66 1.42 ±0.91+
RelA (p65 subunit of NF-κB) 1.20 +0.74 0.95 ±0.44
∗ 1.05 ±0.42 1.07 ±0.45+
IκB-α 1.28 ±1.15 1.30 ±1.14 1.13 ±0.97 1.04 ±0.75
IκB-β 3.17 ±2.05 3.30 ±2.41 2.78 ±1.63 2.86 ±1.62
MMP-9 2.29 ±2.68 1.48 ±1.18 1.56 ±2.02 1.69 ±1.70+
TNFα 1.88 ±1.20 1.70 ±0.93 1.81 ±0.94 2.02 ±1.28+
MIF 0.98 ±0.40 0.84 ±0.31 0.83 ±0.35 0.88 ±0.52
IL-6 1.13 ±0.52 1.05 ±0.46 1.09 ±0.57 1.14 ±0.69
∗: P<0.05 (versus baseline); +: P<0.05 (between the groups for change from baseline).
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Figure 2: Percent changes in proinﬂammatory mRNA expression markers from baseline to week 4.
of the inhibitors to NF-κB( κB-α and IκB-β) apparently
increased. These anti-inﬂammatory eﬀects preceded any
possible eﬀects on glycemia by pioglitazone, and the 4-week
observation period was too short to observe a signiﬁcant
change in HbA1c in this trial. There were, however, several
signs for an improvement in insulin resistance, ß-cell
function, endothelial function, thrombocyte function, and
the metabolic syndrome as indicated by appropriate changes
in the corresponding laboratory biomarkers.
Our observations may provide an insight into the
underlying cellular mechanisms of the short-term glucose-
independent clinical eﬀects of pioglitazone and rosiglitazone
on endothelial and vascular function that were published
recently in nondiabetic subjects and patients with type 2
diabetes. Hetzel and coworkers demonstrated that a three-
week treatment with rosiglitazone did not change blood
glucose or lipid levels of healthy subjects, but increased ﬂow-
mediated, endothelium-dependent vasodilatation starting
already within the ﬁrst day, which was paralleled by a rapid
reduction of proinﬂammatory and prothrombotic biomark-
ers. They suggested a direct eﬀect of PPARγ activation
on endothelial function and inﬂammation, independent of
metabolic action [24].
Another group performed a randomized, placebo-con-
trolled, double-blind crossover trial in 20 patients with type
2 diabetes on eﬀective other oral anti-diabetic medication, to
investigate the eﬀect of treatment with 30mg of pioglitazone
on shear-stress-induced ﬂow-mediated vasodilatation. After
4 weeks, they found an amelioration of endothelial function
in conduit arteries irrespective of signiﬁcant beneﬁcial
changes in the plasma levels of insulin, free fatty acids,
adiponectin, or hsCRP [25]. Also, treatment with pioglita-
zone improved cutaneous microcirculation and endothelial
function independent of glycemic control when compared
with glimepiride [34].
While all these reports provide a conclusive clinical and
biochemical picture regarding a fast anti-inﬂammatory and
antithrombotic eﬀect of PPARγ activation, our results may
contribute to a better understanding of these eﬀects on a
molecular basis. It is known that both abdominal fat and
insulin resistance contribute to vascular disease, especially
in obese patients. In particular, visceral fat contributes to
inﬂammationandendothelialdysfunctionthroughsecretion
of adipokines, like TNFα or IL-6, which are secreted by
the lipid tissue after macrophage recruitment (throughPPAR Research 7
monocyte chemoattractant protein-1 (MCP-1) [11]. Piogli-
tazone has been demonstrated to decrease a variety of
these adipokines in several clinical and experimental studies
[19, 35, 36]. The decrease of several plasma proteins
such as IL-6, TNFα, Angiotensin II, and the increase in
adiponectin in our current experiment is also in line with
these ﬁndings. However, our study does not clarify the
mechanism by which pioglitazone may have down-regulated
macrophage activation in such short time frame. Clinical
studies addressing these eﬀects have only been able to
investigate the fat tissue as a whole, that is, including all
diﬀerent cellular subfractions. Fontana et al. were able to
demonstrate by assessment of arteriovenous concentration
diﬀerences with samples obtained from the portal vein that
visceral fat is a clinically important site of IL-6 secretion,
thus contributing to systemic inﬂammation [37]. It can
be speculated from our results that at least part of the
observed increase in proinﬂammatory cytokines may have
derived from previously circulating mononuclear that had
penetrated into the adipose tissue.
One explanation for the observed results with pioglita-
zone could be a direct eﬀect of the thiazolidinedione on
mononuclearcells.IthasbeenshownthatPPARγ hasdistinct
functions in diﬀerent cell types in the white adipose tissue,
such that pioglitazone reduces macrophage inﬁltration by
inducing apoptotic cell death speciﬁcally in macrophages
through PPARγ activation [38]. Since the macrophages
recruited into the fat tissue are a major source of cytokines
and proteins that are known to maintain systemic inﬂam-
mation [11], a change in their inﬂammatory activity may
be reﬂected by a downregulation of proinﬂammatory mRNA
expression in the circulating mononuclear cells.
Another contributor may also be an indirect eﬀect of
pioglitazone via modiﬁcation of adipokine secretion derived
from diﬀerentiating preadipocytes and other components
of the lipid tissue. The complex nature of the interactions
between lipid tissue, endothelium, muscle, liver, and the
immunesysteminorchestratingsystemicinﬂammationdoes
not allow to draw ultimate conclusions from our observed
eﬀects of pioglitazone at this point, and further research is
required to understand the underlying mechanisms.
What might be clinical implications from our trial? The
observed pleiotropic eﬀects of pioglitazone occur fast and
mainly independent of the metabolic eﬀects of the drug.
This ﬁnding may support an earlier and more frequent use
of this drug in patients who are still well controlled with
other “classical” anti-diabetic drugs but are at elevated risk
for macrovascular disease. We have been able to demonstrate
a signiﬁcant decrease in surrogate markers for systemic
inﬂammation and cardiovascular risk, including intima-
media-thickness, insulin resistance, endothelial function,
hsCRP, MMP-9, or MCP-1 with pioglitazone, while other
anti-diabetic drugs resulting in an equal improvement of
metabolic control had no such eﬀects in diabetic patients
[18, 19, 35]. Pioglitazone, when given by us in compar-
ison or in addition to simvastatin, had an independent
synergistic impact on the cardiovascular risk of patients
with normoglycemic vascular insulin resistance [36, 39].
These clinical ﬁndings are in good agreement with our
current observation of an overall down-regulation of the
inﬂammatory state of circulating monocyte/macrophages by
pioglitazone independent of glycemic control.
In conclusion, the results of our study indicate that
pioglitazone when given in addition to an eﬀective antidia-
betic treatmentwithmetforminand/or sulfonylureainduced
an overall decrease in plasma adipokines and in the
inﬂammatory state of circulating mononuclear cells in
patients with well-controlled type 2 diabetes mellitus, while
a further deterioration was observed with placebo. These
eﬀects occurred independently from glycemic control and
already after short treatment duration. Our ﬁndings may
be helpful to understand the mechanism and nature of the
multiple antiatherosclerotic and antithrombotic eﬀects that
havebeenreportedinrecentcontrolledclinicalinvestigations
and outcome trials comparing thiazolidinediones with other
anti-diabetic drugs.
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